BioAlliance's Loramyc cleared in UK and Denmark

Paris, France-based BioAlliance Pharma says that, following the end of the European Union Mutual Recognition Procedure last December (with France as the reference member state) that it has just received the Marketing Authorization for Loramyc (miconazole Laurid) in the UK and Denmark.

The grant of the MA in the UK represents an important milestone for BioAlliance Pharma, especially with the payment of 2.5 million euros ($3.7 million) by its partner, the Dutch firm SpePharm, according to the terms of their agreement signed last year, which led to the creation of the SpeBio JV for the distribution of Loramyc in Europe (Marketletter March 19, 2007).

"Currently being launched in France, Loramyc will be present on the European market in 2008 as planned. The other main European countries should grant their Marketing Authorization for Loramyc in the very near future," stated Dominique Costantini, chief executive of the French company.